Drugs / Vi-DT Typhoid conjugate vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT03933098 | Nov 2019 → Sep 2020 | typhoid fever | International Vaccine Institute | Unknown | Met primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Vi-DT Typhoid conjugate vaccine | “Vi-DT Typhoid conjugate vaccine” NCT03933098 ↗ |
| Known as | Vi-DT | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03933098 ↗ |
| Route | Intramuscular | “One dose of Vi-DT (typhoid conjugate vaccine) Lot 1 will be administrated intramuscularly at Enrollment visit (Day 0).” NCT03933098 ↗ |